A new concept in the treatment of extravasation injury: Controlled drug delivery systems

Journal of B.U.ON.

Volumn 15, Issue 3, 2010, Pages 592-600

  Konas, Ersoy ^a   Canter, H I ^c   Korkusuz, P ^a   Demir, D ^a,b   Oner, F ^a   Mavili, M E ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

^c ACIBADEM UNIVERSITY   (Turkey)

Author keywords

Adriamycin; Chemotherapy; Chitosan; Controlled release; Extravasation

Indexed keywords

CHITOSAN; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; POLYMER; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EXTRAVASATION; EPITHELIZATION; EXTRAVASATION; IN VITRO STUDY; NONHUMAN; RAT; SINGLE DRUG DOSE; TISSUE NECROSIS; TISSUE REACTION; WISTAR ALBINO GLAXO RAT; WOUND; WOUND HEALING;

ANIMALS; CHITOSAN; DRUG DELIVERY SYSTEMS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RATS; RATS, WISTAR; WOUND HEALING;

EID: 77957734065     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Brown AS, Hoelzer DJ, Piercy SA. Skin necrosis from extravasation of intravenous fluids in children. Plast Reconstr Surg 1979; 64: 145-150.
2. Yosowitz P, Ekland DA, Shaw RC, Parsons RW. Peripheral intravenous infiltration necrosis. Ann Surg 1975; 182: 553-556.
3. Upton J, Mulliken JB, Murray JE. Major intravenous extravasation injuries. Am J Surgery 1979; 137: 497-506. (Pubitemid 9147256)
4. Ignoffo RJ, Friedman MA. Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 1980; 7: 17-27.
5. Harwood KV, Aisner J. Treatment of chemotherapy extravasation: current status. Cancer Treat Rep 1984; 68: 939-945. (Pubitemid 14062892)
6. Bowers DG Jr, Lynch JB. Adriamycin extravasation. Plast Reconstr Surg 1978; 61: 86-92.
7. Scuderi N, Onesti MG. Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg 1994; 32: 39-44. (Pubitemid 24028981)
8. Rudolph R, Stein RS, Pattillo RA. Skin ulcers due to adriamycin. Cancer 1976; 38: 1087-1094.
9. Bussolino F, Ziche M, Wang JM et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991; 87: 986-995.
10. Brown DM, Chung SH, Pasia EN, Khouri RK. Treatment of avascular ulcers with cytokine-induced tissue generation and skin grafting. Am J Surgery 1996; 171: 247-250.
11. Pojda Z, Struzyna J. Treatment of non-healing ulcers with rh-GM-CSF and skin grafts. Lancet 1994; 343 (8905): 1100.
12. Kaplan G, Walsh G, Guido LS et al. Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med 1992; 175: 1717-1728.
13. Marques da Costa R, Jesus FM, Aniceto C, Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Surgery 1997; 173: 165-168. (Pubitemid 27163841)
14. Vargel I, Erdem A, Ertoy D et al. Effects of growth factors on doxorubicin-induced skin necrosis: documentation of histomorphological alterations and early treatment by GM-CSF and G-CSF. Ann Plast Surg 2002; 49: 646-653.
15. Dodane V, Vilivalam VD. Pharmaceutical applications of chitosan. Pharm Sci Technol Today 1998; 6: 246-253.
16. Okamoto Y, Shibazaki K, Minami S, Matsuhashi A, Tanioka S, Shigemasa Y. Evaluation of Chitin and Chitosan on Open Wound Healing in Dogs. J Vet Med Sci 1995; 57: 851-854.
17. Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agents' extravasation injuries: a review. J Clin Oncol 1987; 5: 1116-1126. (Pubitemid 18056020)
18. Loth TS, Eversmann WW Jr. Treatment methods for extravasations of chemotherapeutic agents: a comparative study. J Hand Surg (Am) 1986; 11: 388-396. (Pubitemid 16121397)
19. Wang J, Cortes E, Sinks LF et al. Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease. Cancer 1971; 28: 837-843.
20. Langstein HN, Duman H, Seelig D, Butler CE, Evans GR. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg 2002; 49: 369-374.
21. Jenkins J, Corden BJ. Vesicant activity of chemotherapeutic agents. Cancer Treat Rep 1983; 67: 409.
22. Okano T, Ohnuma T, Efremidis A, Holland JF. Doxorubicin-induced skin ulcer in the piglet. Cancer Treat Rep 1983; 67: 1075-1078. (Pubitemid 14222603)
23. Dorr RT, Alberts DS. Pharmacologic antidotes to experimental doxorubicin skin toxicity: a suggested role for beta-adrenergic compounds. Cancer Treat Rep 1981; 65: 1001-1006.
24. Desai MH, Teres D. Prevention of doxorubicin-induced skin ulcers in the rat and pig with dimethyl sulfoxide (DMSO). Cancer Treat Rep 1982; 66: 1371-1374.
25. Zweig JI, Kabakow B. An apparently effective counter-measure for doxorubicin extravasation. JAMA 1978; 239: 2116.
26. Siegel DM, Giri SN, Scheinholtz RM, Schwartz LW. Characteristics and effect of antiinflammatory drugs on adriamycin-induced inflammation in the mouse paw. Inflammation 1980; 4: 233-247.
27. Cohen MH. Amelioration of adriamycin skin necrosis: an experimental study. Cancer Treat Rep 1979; 63: 1003-1004.
28. Cullen ML. Current interventions for doxorubicin extravasations. Oncol Nurs Forum 1982; 9: 52-53.
29. Coleman JJ 3rd, Walker AP, Didolkar MS. Treatment of adriamycin-induced skin ulcers: a prospective controlled study. J Surg Oncol 1983; 22: 129-135. (Pubitemid 13142055)
30. Malik IA, Zahid M, Haq S, Syed S, Moid I, Waheed I. Effect of subcutaneous injection of granulocyte-macrophage colony stimulating factor (GM-CSF) on healing of chronic refractory wounds. Eur J Surg 1998; 164: 737-744. (Pubitemid 28518455)
31. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in wound healing. Am J Surgery 1998; 176 (2A Suppl): 80S-82S.
32. Sieff CA. Hematopoietic growth factors. J Clin Invest 1987; 79: 1549-1557.
33. Bussolino F, Ziche M, Wang JM et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991; 87: 986-995.
34. Robson M, Kucukcelebi A, Carp SS et al. Effects of granulocyte-macrophage colony-stimulating factor on wound contraction. Eur J Clin Microbiol Infect Dis 1994; 13 (Suppl 2): S41-S46.
35. Zatkone Puskas G. The significance of extravasation in oncological care. Magy Onkol 2008; 52: 75-80.
36. De Ugarte DA, Roberts RL, Lerdluedeeporn P, Stiehm ER, Atkinson JB. Treatment of chronic wounds by local delivery of granulocyte-macrophage colony-stimulating 8 factor in patients with neutrophil dysfunction. Pediatr Surg Int 2002; 18: 517-520. (Pubitemid 41184192)
37. Hoffman AS. Hydrogels for biomedical applications. Drug Deliv Rev 2002; 43: 3-12.
38. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinzki WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20. (Pubitemid 32144788)
39. Wissing S, Muller R. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release 2002; 81: 213-218.